drugset / Trial / NCT06819215
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
Phase 1/2
Recruiting
188 enrolled
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Shandong Cancer Hospital and Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Timeline
- Start
- 2024-10-30
- Primary completion
- 2025-12-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VB15010 | Unknown | — | Oral |